With co-founders from Stanford University and National University of Singapore, Nuevocor aims to develop gene therapies for cardiomyopathies.

Nuevocor, a Singapore-based developer of gene therapies for cardiomyopathies co-founded by Stanford University and National University of Singapore researchers, secured $24m in a series A round yesterday. Pharmaceutical firm and Boehringer Ingelheim co-led the round through subsidiary Boehringer Ingelheim Venture Fund together with EVX Ventures. The round also included Xora Innovation and the state-owned EDBI…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.